Summary of Tongce Medical Conference Call Company Overview - **Company**: Tongce Medical - **Industry**: Dental Medical Services Key Points and Arguments Business Model Transformation - Tongce Medical is transitioning from a high-ticket price model to a more efficient and inclusive healthcare model, achieving revenue of 2.29 billion and a net profit of 514 million in Q1-Q3 2025, indicating strong performance resilience [2][3] Market Dynamics - The company’s implant business has seen a significant increase in the proportion of collective procurement, reaching 75%-80%, with single implant costs in Zhejiang dropping to around 5,000 yuan, indicating a potential demand of 3-4 million implants in the province [2][3] Organizational Reform - The implementation of a "big department system" aims to break local management barriers, allowing for dynamic resource allocation among doctors, which is expected to enhance productivity and support platform expansion [2][7] Digital Infrastructure - Tongce Medical is building an AI platform to integrate its HIS system, managing 7 million existing customers with unique IDs for standardized services and cost reduction [2][8] Orthodontics Strategy - The orthodontics business, under the brand "Yinxiu," is adopting a "full refund for dissatisfaction" policy to lower decision-making barriers and capture price-sensitive markets, aiming to double its customer base [2][10] Financial Projections - The company anticipates a net profit of 670 million in 2026, with a growth rate close to 20%, and is assigned a target price of 67 yuan based on a 45x PE ratio for 2026 [2][11] Industry Insights Long-term Growth Potential - The dental healthcare industry remains a long-term growth sector, with significant potential due to low penetration rates compared to developed countries, particularly in Zhejiang [4][5] Fundamental Changes in the Industry - Recent shifts include a rational return in consumer behavior, with price sensitivity affecting demand, and the impact of collective procurement policies enhancing service accessibility [6] Competitive Landscape - The industry is moving from a high-margin, high-ticket model to one focused on scale and operational efficiency, with domestic brands gaining traction post-price reductions [6] Strategic Responses Market Penetration - Tongce Medical is focusing on grid marketing to penetrate lower-tier markets, targeting a population of approximately 30 million in Zhejiang with affordable product packages [8][9] International Benchmarking - The company aims to replicate the successful market strategies of South Korea, where implant penetration is high, leveraging competitive pricing and local brand strength [9] Risks to Consider - Potential risks include unexpected adjustments in medical service pricing, the effectiveness of ongoing reforms, the risk of medical accidents, and the impact of low-cost product packages on overall profitability [12]

Core Viewpoint - Tongce Medical's executives are planning to repurchase shares, reflecting their confidence in the company's future growth and long-term investment value [1][5]. Group 1: Share Repurchase Plan - The executives, including Chairman Wang Yi and other senior management, plan to increase their holdings between February 13, 2026, and August 13, 2026, with a total investment of no less than 6 million yuan and up to 12 million yuan [1][4]. - The specific amounts for individual executives include Wang Yi, Huang Yuhua, and Zhang Hua each planning to invest between 1.5 million to 3 million yuan, while CFO Xu Guoxi plans to invest 500,000 to 1 million yuan, and Zhao Min plans to invest 1 million to 2 million yuan [1][4]. Group 2: Recent Share Purchases - As of February 13, 2026, the executives have already purchased a total of 38,200 shares for approximately 1.82 million yuan [2][4]. - The breakdown of recent purchases includes Wang Yi buying 10,500 shares for 499,600 yuan, Huang Yuhua buying 10,000 shares for 476,100 yuan, and Zhang Hua buying 10,000 shares for 473,300 yuan [3][4]. Group 3: Company Performance and Future Outlook - Tongce Medical's stock price has seen fluctuations, dropping to 35.54 yuan per share in April 2024 but recovering to 50.03 yuan per share by February 24, 2026, with a total market capitalization of 22.38 billion yuan [2][5]. - The company aims for a 30% year-on-year growth in overall performance for 2026, supported by ongoing reforms and an internal revenue doubling plan [2][7]. - For the first three quarters of 2025, Tongce Medical reported revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit of 514 million yuan, up 3.16% [7].

Core Viewpoint - The company reported steady growth in its financial performance for the first three quarters of 2025, with revenue and net profit showing positive year-on-year changes, indicating resilience in a cautious consumer environment [1][2]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 2.29 billion yuan (+2.56%) and a net profit attributable to shareholders of 514 million yuan (+3.16%) [1]. - In Q3 2025, the company recorded revenue of 842 million yuan (+2.34%) and a net profit of 192 million yuan (+2.15%) [1][2]. - The gross margin for the first three quarters was 41.7%, remaining stable compared to 41.8% in the same period last year [3]. Business Segmentation - The revenue structure for the first three quarters was balanced, with orthodontics and comprehensive services accounting for over half of total revenue [2]. - Orthodontics generated revenue of 426 million yuan, with Q3 revenue of 197 million yuan, representing 25% of Q3 revenue [2]. - Comprehensive services contributed 604 million yuan, with Q3 revenue of 210 million yuan, accounting for 27% of Q3 revenue [2]. Growth Drivers - The recovery in the orthodontics business is driven by two main factors: the implementation of centralized procurement policies stabilizing market expectations and the significant growth in early orthodontic treatments for children [2]. - The number of orthodontic cases in Q3 increased by 10.6%, indicating a recovery trend [2]. Cash Flow and Profitability - The company maintained a low sales expense ratio of 1.17%, reflecting strong brand power and customer acquisition capabilities [3]. - The net cash flow from operating activities for the first three quarters was 682 million yuan (+5.34%), with a cash flow to net profit ratio of 1.11, indicating ample cash flow [3]. Strategic Focus - The company is shifting its core drive from external expansion to enhancing internal efficiency, implementing a "big department system" reform to break down barriers in doctor resources [3]. - Digitalization efforts are aimed at improving productivity among over 1,600 existing doctors [3]. Investment Outlook - The company is actively implementing strategic plans to strengthen talent reserves and expand new hospitals and branches [4]. - Projected net profits for 2025-2027 are estimated at 512 million, 571 million, and 617 million yuan, with year-on-year growth rates of 2.2%, 11.5%, and 8.0% respectively [4]. - A target price of 51.10 yuan is set based on a 40x PE ratio for 2026, maintaining a "recommended" rating [4].